Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime PK/PD target attainment in adult general-ward patients with different renal function
NL-OMON50052Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2019
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ceftazidime in bacterial disease (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: PK-PD target attainment of 50%T>MIC in first 24 hours. Started Oct 2019; status: active, not recruiting.
02
Drugs
ceftazidime
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON50052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50052.